CN Patent

CN115819363B — 酮酰胺类化合物及其制备方法和应用

Assigned to Zhejiang University of Technology ZJUT · Expires 2025-04-01 · 1y expired

What this patent protects

本发明提供一种酮酰胺类化合物及其制备方法和应用，N‑三嗪环取代的酮酰胺类化合物结构新颖，显示一定的抗肿瘤活性，为新药筛选及开发奠定了基础。其制备方法操作方便、成本低，有着广泛的实际应用前景。

USPTO Abstract

本发明提供一种酮酰胺类化合物及其制备方法和应用，N‑三嗪环取代的酮酰胺类化合物结构新颖，显示一定的抗肿瘤活性，为新药筛选及开发奠定了基础。其制备方法操作方便、成本低，有着广泛的实际应用前景。

Drugs covered by this patent

enasidenib-mesylate (ENASIDENIB MESYLATE)

Patent Metadata

Patent number: CN115819363B
Jurisdiction: CN
Classification: —
Expires: 2025-04-01
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang University of Technology ZJUT
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.